FY24 Labor-HHS-Education (HR 5894 / S 2624), Military Construction & Veterans Affairs (HR 4366 / S 2127) and Commerce-Justice-Science (HR 5893 / S 2321) Appropriations; SUPPORT for Patients and Communities Reauthorization Act (HR 4531 / S 2433, S 3106, S 3393); HEAL Act (HR 4007 / S 2809); PAHPA Act (HR 4421 / S 2333); Reentry Act (HR 2400 / S 1165); Due Process Continuity of Care Act (HR 3074 / S 971)
Duration: March 15, 2016
to
present
General Issues: Health Issues , Taxation/Internal Revenue Code , Budget/Appropriations , Alcohol & Drug Abuse , Pharmacy
Spending: about $5,003,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2016: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Health & Human Services - Dept of (HHS)
Related Foreign Entities:
Indivior PLC (Slough, Berkshire, GBR); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2023
In Q4, Indivior Inc had in-house lobbyists. The report was filed on Jan. 22.
Original Filing: 301536160.xml
Lobbying Issues
FY24 Labor-HHS-Education (HR 5894 / S 2624), Military Construction & Veterans Affairs (HR 4366 / S 2127) and Commerce-Justice-Science (HR 5893 / S 2321) Appropriations; SUPPORT for Patients and Communities Reauthorization Act (HR 4531 / S 2433, S 3106, S 3393); HEAL Act (HR 4007 / S 2809); PAHPA Act (HR 4421 / S 2333); Reentry Act (HR 2400 / S 1165); Due Process Continuity of Care Act (HR 3074 / S 971)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Office of Natl Drug Control Policy (NDCP) Substance Abuse & Mental Health Services Administration (SAMHSA)
3rd Quarter, 2023
In Q3, Indivior Inc had in-house lobbyists. The report was filed on Oct. 20, 2023.
Original Filing: 301510900.xml
Lobbying Issues
FY24 Labor-HHS-Education (HR 5894 / S 2624), Military Construction & Veterans Affairs (HR 4366 / S 2127) and Commerce-Justice-Science (HR 5893 / S 2321) Appropriations; SUPPORT Act of 2023 (HR 4531 / S 2433); HEAL Act (HR 4007 / S 2809); PAHPA Act (HR 4421 / S 2333); Reentry Act (HR 2400 / S 1165); Due Process Continuity of Care Act (HR 3074 / S 971)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Office of Natl Drug Control Policy (NDCP) Substance Abuse & Mental Health Services Administration (SAMHSA)
2nd Quarter, 2023
In Q2, Indivior Inc had in-house lobbyists. The report was filed on July 20, 2023.
Original Filing: 301485884.xml
Lobbying Issues
FY24 Labor-HHS-Education and Commerce-Justice-Science appropriations processes, DEA buprenorphine OUD treatment access via telehealth
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Office of Natl Drug Control Policy (NDCP) Substance Abuse & Mental Health Services Administration (SAMHSA)
1st Quarter, 2023
In Q1, Indivior Inc had in-house lobbyists. The report was filed on April 20, 2023.
Original Filing: 301463434.xml
Lobbying Issues
FY24 Labor-HHS-Education and Commerce-Justice-Science appropriations processes, DEA buprenorphine OUD treatment access via telehealth
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Office of Natl Drug Control Policy (NDCP) Substance Abuse & Mental Health Services Administration (SAMHSA)
4th Quarter, 2022
In Q4, Indivior Inc had in-house lobbyists. The report was filed on Jan. 20, 2023.
Original Filing: 301437632.xml
Lobbying Issues
HR955/S285, Medicaid Reentry Act, HR1384/S445 Mainstreaming Addiction Treatment Act; HR2067 Medication Access and Training Expansion Act; S5000 CARA 2.0 Act, FY2023 Labor-HHS-Education and Commerce-Justice-Science Appropriations; HR 7666, Restoring Hope for Mental Health and Well-being Act of 2022; HR 7667, FDA User Fee Amendments of 2022; S 4348, FDASLA Act of 2022; HR 2617, Consolidated Appropriations 2023.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Office of Natl Drug Control Policy (NDCP) Substance Abuse & Mental Health Services Administration (SAMHSA)
3rd Quarter, 2022
In Q3, Indivior Inc had in-house lobbyists. The report was filed on Oct. 20, 2022.
Original Filing: 301415148.xml
Lobbying Issues
HR955/S285, Medicaid Reentry Act, HR1384/S445 Mainstreaming Addiction Treatment Act; HR2067 Medication Access and Training Expansion Act; S5000 CARA 2.0 Act, FY2022 and FY2023 Labor-HHS-Education and Commerce-Justice-Science Appropriations; HR5376 Build Back Better Act re substance use disorder and mental health treatment; HR 7666, Restoring Hope for Mental Health and Well-being Act of 2022; HR 7667, FDA User Fee Amendments of 2022; S 4348, FDASLA Act of 2022; HR 7666, Restoring Hope for Mental Health and Well-being Act of 2022; HR 7667, FDA User Fee Amendments of 2022; S 4348, FDASLA Act of 2022
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Office of Natl Drug Control Policy (NDCP) Substance Abuse & Mental Health Services Administration (SAMHSA)
2nd Quarter, 2022
In Q2, Indivior Inc had in-house lobbyists. The report was filed on July 20, 2022.
Original Filing: 301391403.xml
Lobbying Issues
HR955/S285, Medicaid Reentry Act, HR1384/S445 Mainstreaming Addiction Treatment Act; HR2067 Medication Access and Training Expansion Act; S5000 CARA 2.0 Act, FY2022 Labor-HHS-Education and Commerce-Justice-Science Appropriations; HR5376 Build Back Better Act re substance use disorder and mental health treatment; HR 7666, Restoring Hope for Mental Health and Well-being Act of 2022; HR 7667, FDA User Fee Amendments of 2022; S 4348, FDASLA Act of 2022; HR 7666, Restoring Hope for Mental Health and Well-being Act of 2022; HR 7667, FDA User Fee Amendments of 2022; S 4348, FDASLA Act of 2022
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2022
In Q1, Indivior Inc had in-house lobbyists. The report was filed on April 20, 2022.
Original Filing: 301366038.xml
Lobbying Issues
HR955/S285, Medicaid Reentry Act, HR1384/S445 Mainstreaming Addiction Treatment Act; HR2067 Medication Access and Training Expansion Act; S5000 CARA 2.0 Act, FY2022 Labor-HHS-Education and Commerce-Justice-Science Appropriations; HR5376 Build Back Better Act re substance use disorder and mental health treatment
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2021
In Q4, Indivior Inc had in-house lobbyists. The report was filed on Jan. 20, 2022.
Original Filing: 301334414.xml
Lobbying Issues
HR955/S285, Medicaid Reentry Act, HR1384/S445 Mainstreaming Addiction Treatment Act; HR2067 Medication Access and Training Expansion Act; S5000 CARA 2.0 Act, FY2022 Labor-HHS-Education and Commerce-Justice-Science Appropriations; HR5376 Build Back Better Act re substance use disorder and mental health treatment
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2021
In Q3, Indivior Inc did no lobbying for itself. The report was filed on Oct. 20, 2021.
Original Filing: 301307389.xml
2nd Quarter, 2021
In Q2, Indivior Inc did no lobbying for itself. The report was filed on July 20, 2021.
Original Filing: 301287402.xml
1st Quarter, 2021
In Q1, Indivior Inc did no lobbying for itself. The report was filed on April 20, 2021.
Original Filing: 301260331.xml
4th Quarter, 2020
In Q4, Indivior Inc did no lobbying for itself. The report was filed on Jan. 20, 2021.
Original Filing: 301239451.xml
3rd Quarter, 2020
In Q3, Indivior Inc did no lobbying for itself. The report was filed on Oct. 20, 2020.
Original Filing: 301220299.xml
2nd Quarter, 2020
In Q2, Indivior Inc did no lobbying for itself. The report was filed on July 20, 2020.
Original Filing: 301200677.xml
1st Quarter, 2020
In Q1, Indivior Inc did no lobbying for itself. The report was filed on April 20, 2020.
Original Filing: 301174130.xml
4th Quarter, 2019
In Q4, Indivior Inc had in-house lobbyists. The report was filed on Jan. 21, 2020.
Original Filing: 301125001.xml
Lobbying Issues
Implementation of Support Act; Reimbursement issues; issues related to opioid addiction; issues related to NIH/HHS funding levels; issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act; S. 1895 - Lower Healthcare Costs Act and proposed amendments thereto; issues related to drug pricing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2019
In Q3, Indivior Inc had in-house lobbyists. The report was filed on Oct. 21, 2019.
Original Filing: 301074222.xml
Lobbying Issues
Implementation of Support Act; Reimbursement issues; issues related to opioid addiction; issues related to NIH/HHS funding levels; issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act; S. 1895 - Lower Healthcare Costs Act and proposed amendments thereto; issues related to drug pricing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2019
In Q2, Indivior Inc had in-house lobbyists. The report was filed on July 22, 2019.
Original Filing: 301056438.xml
Lobbying Issues
Implementation of Support Act; Reimbursement issues; issues related to opioid addiction; issues related to NIH/HHS funding levels; issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act; S. 1895 - Lower Healthcare Costs Act and proposed amendments thereto; issues related to drug pricing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2019
In Q1, Indivior Inc had in-house lobbyists. The report was filed on April 22, 2019.
Original Filing: 301035264.xml
Lobbying Issues
Implementation of Support Act; Reimbursement issues; issues related to opioid addiction; issues related to NIH/HHS funding levels; issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2018
In Q4, Indivior Inc had in-house lobbyists. The report was filed on Jan. 22, 2019.
Original Filing: 301016166.xml
Lobbying Issues
Issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act. Implementation of the CARA Act and its nurse practitioner/physician assistant prescribing provisions. S.2456 CARA 2.0 Act of 2018; S.916 Protecting Patient Access to Emergency Medications Act of 2017; H.R. 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018; H.R. 6 Support for Patients and Communities Act; H.R. 5102 Substance Use Disorder Workforce Loan Repayment Act of 2018; H.R. 5176 Preventing Overdoses While in Emergency Rooms Act of 2018; H.R. 5272 To provide additional guidance to grantees seeking funding to treat or prevent mental health or substance use disorders; H.R. 5327 Comprehensive Opioid Recovery Centers Act of 2018; H.R. 5483 Special Registration for Telemedicine Clarification Act of 2018; H.R. 5587 Peer Support Communities of Recovery Act; S. 2680 Opioid Crisis Response Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act. S. 916 Protecting Patient Access to Emergency Medications Act of 2017; S.2456 CARA 2.0 Act of 2018; H.R. 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018; H.R. 6 Support for Patients and Communities Act; H.R. 5102 Substance Use Disorder Workforce Loan Repayment Act of 2018; H.R. 5176 Preventing Overdoses While in Emergency Rooms Act of 2018; H.R. 5272 To provide additional guidance to grantees seeking funding to treat or prevent mental health or substance use disorders; H.R. 5327 Comprehensive Opioid Recovery Centers Act of 2018; H.R. 5483 Special Registration for Telemedicine Clarification Act of 2018; H.R. 5587 Peer Support Communities of Recovery Act; S. 2680 Opioid Crisis Response Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2018
In Q3, Indivior Inc had in-house lobbyists. The report was filed on Oct. 22, 2018.
Original Filing: 300998051.xml
Lobbying Issues
Issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act. Implementation of the CARA Act and its nurse practitioner/physician assistant prescribing provisions. S.2456 CARA 2.0 Act of 2018; S.916 Protecting Patient Access to Emergency Medications Act of 2017; H.R. 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018; H.R. 6 Support for Patients and Communities Act; H.R. 5102 Substance Use Disorder Workforce Loan Repayment Act of 2018; H.R. 5176 Preventing Overdoses While in Emergency Rooms Act of 2018; H.R. 5272 To provide additional guidance to grantees seeking funding to treat or prevent mental health or substance use disorders; H.R. 5327 Comprehensive Opioid Recovery Centers Act of 2018; H.R. 5483 Special Registration for Telemedicine Clarification Act of 2018; H.R. 5587 Peer Support Communities of Recovery Act; S. 2680 Opioid Crisis Response Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act. S. 916 Protecting Patient Access to Emergency Medications Act of 2017; S.2456 CARA 2.0 Act of 2018; H.R. 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018; H.R. 6 Support for Patients and Communities Act; H.R. 5102 Substance Use Disorder Workforce Loan Repayment Act of 2018; H.R. 5176 Preventing Overdoses While in Emergency Rooms Act of 2018; H.R. 5272 To provide additional guidance to grantees seeking funding to treat or prevent mental health or substance use disorders; H.R. 5327 Comprehensive Opioid Recovery Centers Act of 2018; H.R. 5483 Special Registration for Telemedicine Clarification Act of 2018; H.R. 5587 Peer Support Communities of Recovery Act; S. 2680 Opioid Crisis Response Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2018
In Q2, Indivior Inc had in-house lobbyists. The report was filed on July 20, 2018.
Original Filing: 300974991.xml
Lobbying Issues
Issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act. Implementation of the CARA Act and its nurse practitioner/physician assistant prescribing provisions. S.2456 CARA 2.0 Act of 2018; S.916 Protecting Patient Access to Emergency Medications Act of 2017; H.R. 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018; H.R. 6 Support for Patients and Communities Act; H.R. 5102 Substance Use Disorder Workforce Loan Repayment Act of 2018; H.R. 5176 Preventing Overdoses While in Emergency Rooms Act of 2018; H.R. 5272 To provide additional guidance to grantees seeking funding to treat or prevent mental health or substance use disorders; H.R. 5327 Comprehensive Opioid Recovery Centers Act of 2018; H.R. 5483 Special Registration for Telemedicine Clarification Act of 2018; H.R. 5587 Peer Support Communities of Recovery Act; S. 2680 Opioid Crisis Response Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act. S. 916 Protecting Patient Access to Emergency Medications Act of 2017; S.2456 CARA 2.0 Act of 2018; H.R. 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018; H.R. 6 Support for Patients and Communities Act; H.R. 5102 Substance Use Disorder Workforce Loan Repayment Act of 2018; H.R. 5176 Preventing Overdoses While in Emergency Rooms Act of 2018; H.R. 5272 To provide additional guidance to grantees seeking funding to treat or prevent mental health or substance use disorders; H.R. 5327 Comprehensive Opioid Recovery Centers Act of 2018; H.R. 5483 Special Registration for Telemedicine Clarification Act of 2018; H.R. 5587 Peer Support Communities of Recovery Act; S. 2680 Opioid Crisis Response Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2018
In Q1, Indivior Inc had in-house lobbyists. The report was filed on April 20, 2018.
Original Filing: 300954130.xml
Lobbying Issues
Issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act. Implementation of the CARA Act and its nurse practitioner/physician assistant prescribing provisions. S.2456 CARA 2.0 Act of 2018; S.916 Protecting Patient Access to Emergency Medications Act of 2017; H.R. 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act. S. 916 Protecting Patient Access to Emergency Medications Act of 2017; S.2456 CARA 2.0 Act of 2018; H.R. 5202 Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2017
In Q4, Indivior Inc had in-house lobbyists. The report was filed on Jan. 22, 2018.
Original Filing: 300935687.xml
Lobbying Issues
Issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act. H.R. 1492 Medical Controlled Substances Transportation Act of 2017. H.R. 304/S.916 Protecting Patient Access to Emergency Medications Act of 2017. Implementation of the CARA Act and its nurse practitioner/physician assistant prescribing provisions; H.R. 1628 American Health Care Act of 2017; H.R. 2430/ S. 934 FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act. H.R. 1492 Medical Controlled Substances Transportation Act of 2017. H.R. 304/S. 916 Protecting Patient Access to Emergency Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1 (Tax Cuts and Jobs Act).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, Indivior Inc had in-house lobbyists. The report was filed on Oct. 20, 2017.
Original Filing: 300913624.xml
Lobbying Issues
Issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act. H.R. 1492 Medical Controlled Substances Transportation Act of 2017. H.R. 304/S.916 Protecting Patient Access to Emergency Medications Act of 2017. Implementation of the CARA Act and its nurse practitioner/physician assistant prescribing provisions; H.R. 1628 American Health Care Act of 2017; H.R. 2430/ S. 934 FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act. H.R. 1492 Medical Controlled Substances Transportation Act of 2017. H.R. 304/S. 916 Protecting Patient Access to Emergency Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Tax reform.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, Indivior Inc had in-house lobbyists. The report was filed on July 20, 2017.
Original Filing: 300892620.xml
Lobbying Issues
Issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act. H.R. 1492 Medical Controlled Substances Transportation Act of 2017. H.R. 304/S.916 Protecting Patient Access to Emergency Medications Act of 2017. Implementation of the CARA Act and its nurse practitioner/physician assistant prescribing provisions; H.R. 1628 American Health Care Act of 2017; H.R. 2430/ S. 934 FDA Reauthorization Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act. H.R. 1492 Medical Controlled Substances Transportation Act of 2017. H.R. 304/S. 916 Protecting Patient Access to Emergency Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Tax reform.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, Indivior Inc had in-house lobbyists. The report was filed on April 20, 2017.
Original Filing: 300874960.xml
Lobbying Issues
Issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act. H.R. 1492 Medical Controlled Substances Transportation Act of 2017. H.R. 304 Protecting Patient Access to Emergency Medications Act of 2017. Implementation of the CARA Act and its nurse practitioner/physician assistant prescribing provisions.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to funding for CARA, medication assisted treatment and 21st Century Cures Act. H.R. 1492 Medical Controlled Substances Transportation Act of 2017. H.R. 304 Protecting Patient Access to Emergency Medications Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Tax reform.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, Indivior Inc had in-house lobbyists. The report was filed on Jan. 23, 2017.
Original Filing: 300856107.xml
Lobbying Issues
H.R. 2872 Opioid Addiction Treatment Modernization Act.
H.R. 1821/S. 707 Opioid Overdose Reduction Act of 2015.
H.R. 2536/S. 1455 TREAT ACT.
H.R. 953/S. 524 Comprehensive Addiction and Recovery Act of 2016.
H.R. 5046 Comprehensive Opioid Abuse Reduction Act.
H.R. 4981 Opioid Use Disorder Treatment Expansion & Modernization Act.
Controlled Substances act issues.
H.R. 6 21st Century Cures Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 2872 Opioid Addiction Treatment Modernization Act.
H.R. 1821/S. 707 Opioid Overdose Reduction Act of 2015.
H.R. 2536/S. 1455 TREAT ACT.
H.R. 953/S. 524 Comprehensive Addiction and Recovery Act of 2016.
H.R. 5046 Comprehensive Opioid Abuse Reduction Act.
H.R. 4981 Opioid Use Disorder Treatment Expansion & Modernization Act.
Controlled Substances act issues.
H.R. 6 21st Century Cures Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
(Public Law 114-113) Consolidated Appropriations Act, 2016.
H.R. 3020 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016.
H.R. 953/S. 524 Comprehensive Addiction and Recovery Act of 2016.
H.R. 6 21st Century Cures Act.
H.R. 2028 Further Continuing and Security Assistance Appropriations Act.
H.R. 5325 Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriation Act, 2017, and Zika Response and Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2016
In Q3, Indivior Inc had in-house lobbyists. The report was filed on Oct. 20, 2016.
Original Filing: 300834783.xml
Lobbying Issues
H.R. 2872 Opioid Addiction Treatment Modernization Act.
H.R. 1821/S. 707 Opioid Overdose Reduction Act of 2015.
H.R. 2536/S. 1455 TREAT ACT.
H.R. 953/S. 524 Comprehensive Addiction and Recovery Act of 2016.
H.R. 5046 Comprehensive Opioid Abuse Reduction Act.
H.R. 4981 Opioid Use Disorder Treatment Expansion & Modernization Act.
Controlled Substances act issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 2872 Opioid Addiction Treatment Modernization Act.
H.R. 1821/S. 707 Opioid Overdose Reduction Act of 2015.
H.R. 2536/S. 1455 TREAT ACT.
H.R. 953/S. 524 Comprehensive Addiction and Recovery Act of 2016.
H.R. 5046 Comprehensive Opioid Abuse Reduction Act.
H.R. 4981 Opioid Use Disorder Treatment Expansion & Modernization Act.
Controlled Substances act issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
(Public Law 114-113) Consolidated Appropriations Act, 2016.
H.R. 3020 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016.
H.R. 953/S. 524 Comprehensive Addiction and Recovery Act of 2016.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2016
In Q2, Indivior Inc had in-house lobbyists. The report was filed on July 20, 2016.
Original Filing: 300821116.xml
Lobbying Issues
H.R. 2872 Opioid Addiction Treatment Modernization Act.
H.R. 1821/S. 707 Opioid Overdose Reduction Act of 2015.
H.R. 2536/S. 1455 TREAT ACT.
H.R. 953/S. 524 Comprehensive Addiction and Recovery Act of 2015.
H.R. 5046 Comprehensive Opioid Abuse Reduction Act.
H.R. 4981 Opioid Use Disorder Treatment Expansion & Modernization Act.
Controlled Substances act issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 2872 Opioid Addiction Treatment Modernization Act.
H.R. 1821/S. 707 Opioid Overdose Reduction Act of 2015.
H.R. 2536/S. 1455 TREAT ACT.
H.R. 953/S. 524 Comprehensive Addiction and Recovery Act of 2015.
H.R. 5046 Comprehensive Opioid Abuse Reduction Act.
H.R. 4981 Opioid Use Disorder Treatment Expansion & Modernization Act.
Controlled Substances act issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
(Public Law 114-113) Consolidated Appropriations Act, 2016.
H.R. 3020 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2016
In Q1, Indivior Inc had in-house lobbyists. The report was filed on April 20, 2016.
Original Filing: 300802875.xml
Lobbying Issues
H.R. 2872 Opioid Addiction Treatment Modernization Act.
H.R. 1821/S. 707 Opioid Overdose Reduction Act of 2015.
H.R. 2536/S. 1455 TREAT ACT.
H.R. 953/S. 524 Comprehensive Addiction and Recovery Act of 2015.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Alcohol & Drug Abuse Health Issues Pharmacy
1st Quarter, 2016
Indivior Inc filed a lobbying registration on April 19, 2016 for in-house lobbying efforts, effective March 15, 2016.
Original Filing: 300794488.xml
Issue(s) they said they’d lobby about: Issues pertaining to pharmaceutical drugs and addiction treatments. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate